About Dynein axonemal heavy chain 10
Dynein axonemal heavy chain 10 (DNAH10) is a protein
from Homo sapiens identified by UniProt accession
Q8IVF4, 4471 residues long.
MolForge cross-references it against 0 known binders and
183 disease associations.
Target properties
| Protein name | Dynein axonemal heavy chain 10 |
|---|
| UniProt accession | Q8IVF4 |
|---|
| Gene | DNAH10 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 4471 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (4471 residues)
MVPEEVEVEI DEIPVLSEEG EEEEETYSQK VESVDKVRAK RVSLRTESLG QPLNREDEEM DKEISEKLPS KRTAKHIMEK MHLHMLCTPL PEEFLDQNVV FFLRNTKEAI SEATDMKEAM EIMPETLEYG IINANVLHFL KNIICQVFLP ALSFNQHRTS TTVGVTSGEV SNSSEHESDL PPMPGEAVEY HSIQLIRDEF LMNVQKFASN IQRTMQQLEG EIKLEMPIIS VEGEVSDLAA DPETVDILEQ CVINWLNQIS TAVEAQLKKT PQGKGPLAEI EFWRERNATL SALHEQTKLP IVRKVLDVIK ESDSMLVANL QPVFTELFKF HTEASDNVRF LSTVERYFKN ITHGSGFHVV LDTIPAMMSA LRMVWIISRH YNKDERMIPL MERIAWEIAE RVCRVVNLRT LFKENRASAQ SKTLEARNTL RLWKKAYFDT RAKIEASGRE DRWEFDRKRL FERTDYMATI CQDLSDVLQI LEEFYNIFGP ELKAVTGDPK RIDDVLCRVD GLVTPMENLT FDPFSIKSSQ FWKYVMDEFK IEVLIDIINK IFVQNLENPP LYKNHPPVAG AIYWERSLFF RIKHTILRFQ EVQEILDSDR GQEVKQKYLE VGRTMKEYED RKYEQWMEVT EQVLPALMKK SLLTKSSIAT EEPSTLERGA VFAINFSPAL REIINETKYL EQLGFTVPEL ARNVALQEDK FLRYTAGIQR MLDHYHMLIG TLNDAESVLL KDHSQELLRV FRSGYKRLNW NSLGIGDYIT GCKQAIGKFE SLVHQIHKNA DDISSRLTLI EAINLFKYPA AKSEEELPGV KEFFEHIERE RASDVDHMVR WYLAIGPLLT KVEGLVVHTN TGKAPKLASY YKYWEKKIYE VLTKLILKNL QSFNSLILGN VPLFHTETIL TAPEIILHPN TNEIDKMCFH CVRNCVEITK HFVRWMNGSC IECPPQKGEE EEVVIINFYN DISLNPQIIE QAVMIPQNVH RILINLMKYL QKWKRYRPLW KLDKAIVMEK FAAKKPPCVA YDEKLQFYSK IAYEVMRHPL IKDEHCIRLQ LRHLANTVQE NAKSWVISLG KLLNESAKEE LYNLHEEMEH LAKNLRKIPN TLEDLKFVLA TIAEIRSKSL VMELRYRDVQ ERYRTMAMYN LFPPDAEKEL VDKIESIWSN LFNDSVNVEH ALGDIKRTFT ELTRGEIMNY RVQIEEFAKR FYSEGPGSVG DDLDKGVELL GVYERELARH EKSRQELANA EKLFDLPITM YPELLKVQKE MSGLRMIYEL YEGLKVAKEE WSQTLWINLN VQILQEGIEG FLRALRKLPR PVRGLSVTYY LEAKMKAFKD SIPLLLDLKN EALRDRHWKE LMEKTSVFFE MTETFTLENM FAMELHKHTD VLNEIVTAAI KEVAIEKAVK EILDTWENMK FTVVKYCKGT QERGYILGSV DEIIQSLDDN TFNLQSISGS RFVGPFLQTV HKWEKTLSLI GEVIEIWMLV QRKWMYLESI FIGGDIRSQL PEEAKKFDNI DKVFKRIMGE TLKDPVIKRC CEAPNRLSDL QNVSEGLEKC QKSLNDYLDS KRNAFPRFFF ISDDELLSIL GSSDPLCVQE HMIKMYDNIA SLRFNDGDSG EKLVSAMISA EGEVMEFRKI LRAEGRVEDW MTAVLNEMRR TNRLITKEAI FRYCEDRSRV DWMLLYQGMV VLAASQVWWT WEVEDVFHKA QKGEKQAMKN YGRKMHRQID ELVTRITMPL SKNDRKKYNT VLIIDVHARD IVDSFIRGSI LEAREFDWES QLRFYWDREP DELNIRQCTG TFGYGYEYMG LNGRLVITPL TDRIYLTLTQ ALSMYLGGAP AGPAGTGKTE TTKDLAKALG LLCVVTNCGE GMDYRAVGKI FSGLAQCGAW GCFDEFNRID ASVLSVISSQ IQTIRNALIH QLTTFQFEGQ EISLDSRMGI FITMNPGYAG RTELPESVKA LFRPVVVIVP DLQQICEIML FSEGFLEAKT LAKKMTVLYK LAREQLSKQY HYDFGLRALK SVLVMAGELK RGSSDLREDV VLMRALRDMN LPKFVFEDVP LFLGLISDLF PGLDCPRVRY PDFNDAVEQV LEENGYAVLP IQVDKVVQMF ETMLTRHTTM VVGPTRGGKS VVINTLCQAQ TKLGLTTKLY ILNPKAVSVI ELYGILDPTT RDWTDGVLSN IFREINKPTD KKERKYILFD GDVDALWVEN MNSVMDDNRL LTLANGERIR LQAHCALLFE VGDLQYASPA TVSRCGMVYV DPKNLKYRPY WKKWVNQIPN KVEQYNLNSL FEKYVPYLMD VIVEGIVDGR QAEKLKTIVP QTDLNMVTQL AKMLDALLEG EIEDLDLLEC YFLEALYCSL GASLLEDGRM KFDEYIKRLA SLSTVDTEGV WANPGELPGQ LPTLYDFHFD NKRNQWVPWS KLVPEYIHAP ERKFINILVH TVDTTRTTWI LEQMVKIKQP VIFVGESGTS KTATTQNFLK NLSEETNIVL MVNFSSRTTS MDIQRNLEAN VEKRTKDTYG PPMGKRLLVF MDDMNMPRVD EYGTQQPIAL LKLLLEKGYL YDRGKELNCK SIRDLGFIAA MGKAGGGRNE VDPRFISLFS VFNVPFPSEE SLHLIYSSIL KGHTSTFHES IVAVSGKLTF CTLALYKNIV QDLPPTPSKF HYIFNLRDLS RVFNGLVLTN PERFQTVAQM VRVWRNECLR VFHDRLISET DKQLVQQHIG SLVVEHFKDD VEVVMRDPIL FGDFQMALHE GEPRIYEDIQ DYEAAKALFQ EILEEYNESN TKMNLVLFDD ALEHLTRVHR IIRMDRGHAL LVGVGGSGKQ SLSRLAAFTA SCEVFEILLS RGYSENSFRE DLKSLYLKLG IENKAMIFLF TDAHVAEEGF LELINNMLTS GIVPALFSEE EKESILSQIG QEALKQGMGP AKESVWQYFV NKSANNLHIV LGMSPVGDTL RTWCRNFPGM VNNTGIDWFM PWPPQALHAV AKSFLGYNPM IPAENIENVV KHVVLVHQSV DHYSQQFLQK LRRSNYVTPK NYLDFINTYS KLLDEKTQCN IAQCKRLDGG LDKLKEATIQ LDELNQKLAE QKIVLAEKSA ACEALLEEIA VNTAVAEEKK KLAEEKAMEI EEQNKVIAME KAEAETTLAE VMPILEAAKL ELQKLDKSDV TEIRSFAKPP KQVQTVCECI LIMKGYKELN WKTAKGVMSD PNFLRSLMEI DFDSITQSQV KNIKGLLKTL NTTTEEMEAV SKAGLGMLKF VEAVMGYCDV FREIKPKREK VARLERNFYL TKRELERIQN ELAAIQKELE TLGAKYEAAI LEKQKLQEEA EIMERRLIAA DKLISGLGSE NIRWLNDLDE LMHRRVKLLG DCLLCAAFLS YEGAFTWEFR DEMVNRIWQN DILEREIPLS QPFRLESLLT DDVEISRWGS QGLPPDELSV QNGILTTRAS RFPLCIDPQQ QALNWIKRKE EKNNLRVASF NDPDFLKQLE MSIKYGTPFL FRDVDEYIDP VIDNVLEKNI KVSQGRQFII LGDKEVDYDS NFRLYLNTKL ANPRYSPSVF GKAMVINYTV TLKGLEDQLL SVLVAYERRE LEEQREHLIQ ETSENKNLLK DLEDSLLREL ATSTGNMLDN VDLVHTLEET KSKATEVSEK LKLAEKTALD IDRLRDGYRP AARRGAILFF VLSEMALVNS MYQYSLIAFL EVFRLSLKKS LPDSILMKRL RNIMDTLTFS IYNHGCTGLF ERHKLLFSFN MTIKIEQAEG RVPQEELDFF LKGNISLEKS KRKKPCAWLS DQGWEDIILL SEMFSDNFGQ LPDDVENNQT VWQEWYDLDS LEQFPVPLGY DNNITPFQKL LILRCFRVDR VYRAVTDYVT VTMGEKYVQP PMISFEAIFE QSTPHSPIVF ILSPGSDPAT DLMKLAERSG FGGNRLKFLA MGQGQEKVAL QLLETAVARG QWLMLQNCHL LVKWLKDLEK SLERITKPHP DFRLWLTTDP TKGFPIGILQ KSLKVVTEPP NGLKLNMRAT YFKISHEMLD QCPHPAFKPL VYVLAFFHAV VQERRKFGKI GWNVYYDFNE SDFQVCMEIL NTYLTKAFQQ RDPRIPWGSL KYLIGEVMYG GRAIDSFDRR ILTIYMDEYL GDFIFDTFQP FHFFRNKEVD YKIPVGDEKE KFVEAIEALP LANTPEVFGL HPNAEIGYYT QAARDMWAHL LELQPQTGES SSGISRDDYI GQVAKEIENK MPKVFDLDQV RKRLGTGLSP TSVVLLQELE RFNKLVVRMT KSLAELQRAL AGEVGMSNEL DDVARSLFIG HIPNIWRRLA PDTLKSLGNW MVYFLRRFSQ YMLWVTESEP SVMWLSGLHI PESYLTALVQ ATCRKNGWPL DRSTLFTQVT KFQDADEVNE RAGQGCFVSG LYLEGADWDI EKGCLIKSKP KVLVVDLPIL KIIPIEAHRL KLQNTFRTPV YTTSMRRNAM GVGLVFEADL FTTRHISHWV LQGVCLTLNS D
Explore Dynein axonemal heavy chain 10 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets